Today’s guest is Anne Phelan, Chief Scientific Officer at BenevolentAI. Benevolent is a global leader in applying advanced AI to accelerate pharmaceutical drug discovery, leveraging the latest technologies to uncover new biology, predict novel targets, and develop treatments for some of the world’s most complex diseases. Anne joins the program today to give us an insider’s view into how her team uses a suite of cutting-edge tools to predict the properties of a drug, as well as its pharmacology and suitability for dosing in humans. This episode is sponsored by BenevolentAI. To learn more about Emerj Media and how to reach the Emerj audience, visit emerj.com/ad1.

Today’s guest is Dr. Dan Elton, a Data Scientist at the Mass General Brigham Data Science Office. He’s also a fellow at the Foresight Institute and previously served as a staff scientist at the National Institutes of Health. Dan returns to the Emerj podcast platform following his appearance on the ‘AI in Business’ podcast to clarify his vision for what he sees as the future of ‘preventative care’ as healthcare workflows fuse with advanced technologies. Throughout the episode, Dr. Elton clarifies the industry trends and market forces keeping the sector locked in a ‘reactive’ status quo and specifically how healthcare leaders can leverage new AI capabilities to build proactive approaches to patient care through new systems. If you’ve enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!

Today’s guest is Prashant Natajaran, Vice President of Strategy and Products at H2O.ai. H2O.ai is a tech company whose platform, the H2O AI Cloud, enables businesses, government entities, nonprofits, and academic institutions to make, operate, and innovate with different AI capabilities like machine learning and AI-enhanced middleware. Prashant joins Emerj CEO and Head of Research Daniel Faggella on today’s episode to discuss the impact generative AI is having on the healthcare industry and what leaders can do to drive adoption safely across the enterprise. To discover more AI use cases, best practice guides, white papers, frameworks, and more, join Emerj Plus at emerj.com/p1.

Today’s guest is Asif Hasan, Co-founder of Quantiphi. Quantiphi is an AI-first digital engineering company that designs AI-driven services and platforms for broad applications across industries. In conversation with Emerj CEO and Head of Research Daniel Faggella, Asif discusses reducing hallucinations in healthcare language models and the latest developments in AI’s impact on drug discovery for rare disorders. If you’ve enjoyed or benefited from the insights in this episode, consider leaving us a five-star review on Apple Podcasts and let us know what you learned or liked most about this show or what you’d like to see in the future. 

Today, we are proud to introduce the latest addition to our burgeoning podcast platform: The ‘AI in Healthcare and Life Sciences’ podcast! Join the Emerj staff as we converse with Fortune 500 leaders and those at the cutting edge of technological transformations to look at high-level industry trends. Together, we try to anticipate how AI capabilities may be able to solve ensuing business challenges while improving experiences for patients and caretakers alike. Check out our pilot episode, featuring a profile of prevalent AI-related healthcare and life sciences trends, as well as previous episodes of our flagship ‘AI in Business’ podcast featuring prominent leaders across both sectors.